Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. METHODS: We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. RESULTS: Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. CONCLUSIONS: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,930
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723 · cited 2×
“(%) <35 yr 35–60 yr ≥60 yr 76 (27) 177 (62) 32 (11)”
BackgroundSlovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 2×
“(%)* t(15;17) t(8;21) inv(16)/t(16;16) +8 +11 +21 ¡5 ¡5(q) ¡7 ¡7(q) 3q t(6;9) t(9;22) t(11q23) Complex karyotype (>3 chromosomal abnormalities) Other abnormal karyotypes Normal karyotype Not determined 18 (6) 22 (8) 19 (7) 26 (9) 7 (2) 2 (1) 3 (1) 1 (<1) 13 (5) 7 (2) 6 (2) 4 (1) 2 (1) 19 (7) 11 (4) 60 (21) 119 (42) 10…”
Research works printed but not linked: 1
- 17. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood (in press).
Cited by
Items 501–600 of 1,000
Culver‐Cochran, A. E., Hassan, A., Hueneman, K. M., Choi, K., Ma, A. I., VanCauwenbergh, B., O'Brien, E. J., Wunderlich, M., Perentesis, J. P., & Starczynowski, D. T. (2024) · Nature Communications · doi:10.1038/s41467-024-53629-z · Cited by 43
Meyer, S., Fergusson, W. D., Whetton, A. D., Moreira-Leite, F. F., Pepper, S. D. V., Miller, C. J., Saunders, E., White, D. J., Will, A., Eden, T. O. B., et al. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20417 · Cited by 41
“Overexpression of EVI1 predefines gene expression profile of a specific subgroup of AML, and is associated in most cases with a complex karyotype that commonly includes chromosome 7 abnormalities (Barjesteh van Waalwijk van DoornKhosrovani et al., 2003; Valk et al., 2004).”
BackgroundGuo, D., Zhao, Y., Wang, N., You, N., Zhu, W., Zhang, P., Ren, Q., Yin, J., Cheng, T., & Ma, X. (2021) · Blood · doi:10.1182/blood.2020008229 · Cited by 36
Tribbles: ‘puzzling’ regulators of cell signalling
Kiss‐Toth, E. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390684 · Cited by 40
Insights into cell ontogeny, age, and acute myeloid leukemia
Chaudhury, S., Morison, J., Gibson, B. E. S., & Keeshan, K. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.008 · Cited by 40
“successfully predict cytogenetic risk categories[73, 74].”
BackgroundPrognostic impact of RAS mutations in patients with myelodysplastic syndrome
Al‐Kali, A., Quintás‐Cardama, A., Luthra, R., Bueso-Ramos, C., Pierce, S. A., Kadia, T. M., Borthakur, G. M., Estrov, Z. E., Jabbour, E. J., Faderl, S. H., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23410 · Cited by 37
“The reported incidence of RAS mutations ranges widely between 2 and 48% [17–25] However, most large cohorts have reported the presence of RAS mutations in approximately 10% of patients [28] In addition, N-RAS has been found mutated and constitutively activated in 10% of patients with AML, whereas K-RAS is mutated in 5…”
BackgroundPurity for clarity: the need for purification of tumor cells in DNA microarray studies
de Ridder, D., van der Linden, C. E., Schonewille, T., Dik, W. A., Reinders, M. J. T., van Dongen, J. J. M., & Staal, F. J. T. (2005) · Leukemia · doi:10.1038/sj.leu.2403685 · Cited by 37
Liu, T., Jankovic, D. L., Brault, L., Ehret, S., Baty, F., Stavropoulou, V., Rossi, V., Biondi, A., & Schwaller, J. (2010) · Leukemia · doi:10.1038/leu.2009.272 · Cited by 38
Randomization in Laboratory Procedure Is Key to Obtaining Reproducible Microarray Results
Yang, H., Harrington, C. A., Vartanian, K. A., Coldren, C. D., Hall, R., & Churchill, G. A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003724 · Cited by 42
“Accumulated data can be used to classify new samples [7–10].”
BackgroundMethodRNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes
Fleischmann, K., Pagel, P., Schmid, I., & Roscher, A. A. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-27 · Cited by 40
“Gene sets associated to leukemia were extracted from FunDO and from leukemia patient studies [1,20-23] and transformed to the official gene symbols.”
BackgroundMethodVerhaak, R. G. W., Sanders, M. A., Bijl, M., Delwel, R., Horsman, S., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., & Valk, P. J. M. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-337 · Cited by 37
Self-citationvan Delft, F. W., Bellotti, A. G., Luo, Z., Jones, L. K., Patel, N. R., Yiannikouris, O., Hill, A. S., Hubank, M. J. F., Kempski, H. M., Fletcher, D., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05545.x · Cited by 37
“…have been shown to be prognostic (Yagi et al, 2003) and suggest clues to the underlying mechanisms of leukaemogenesis peculiar for each translocation (Schoch et al, 2002; Debernardi et al, 2003; Ferrando et al, 2003; Yagi et al, 2003; Bullinger et al, 2004; Ross et al, 2004; Valk et al, 2004).”
BackgroundLabrie, F., Luu-The, V., Martel, C., Chernomoretz, A., Calvo, E. L., Morissette, J., & Labrie, C. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.03.006 · Cited by 38
Dissection of a metastatic gene expression signature into distinct components
Roepman, P., de Koning, E., van Leenen, D., de Weger, R. A., Kummer, J. A., Slootweg, P. J., & Holstege, F. C. (2006) · Genome Biology · doi:10.1186/gb-2006-7-12-r117 · Cited by 36
“Such studies have been used to identify new subtypes of cancer [4-7].”
MethodThe Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells
Staber, P. B., Zhang, P., Ye, M., Welner, R. S., Levantini, E., Di Ruscio, A., Ebralidze, A. K., Bach, C., Zhang, H., Zhang, J., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550855 · Cited by 36
“We first evaluated the relative PU.1 expression in leukemia patients by using the gene expression data set (Affymetrix U133A GeneChips) of the Erasmus Rotterdam cohort comprising 285 well-characterized patients with AML.37 PU.1 expression is shown as black bars in respect to hierarchical clusters that reflect distinct…”
MethodSelf-citationCuesta‐Mateos, C., Terrón, F., & Herling, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.736758 · Cited by 54
Reikvam, H., Tamburini, J., Skrede, S., Holdhus, R., Poulain, L., Ersvær, E., Hatfield, K. J., & Bruserud, Ø. (2013) · British Journal of Haematology · doi:10.1111/bjh.12611 · Cited by 36
“To validate the microarray data, we also analysed the expression of the CDC25B gene and the two housekeeping genes B2M and ACTB by rt-PCR (Weisser et al, 2004).”
MethodMolecular mechanisms underlying deregulation of C/EBPα in acute myeloid leukemia
Reckzeh, K., & Cammenga, J. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0573-1 · Cited by 43
“using unsupervised clustering revealed that C/EBPa mutant AMLs identify a unique subgroup of AML that is characterized by a distinct expression pattern [ 54 ].”
MethodRECONSTRUCTING TUMOR PHYLOGENIES FROM HETEROGENEOUS SINGLE-CELL DATA
Pennington, G., SMITH, C. A., Shackney, S. E., & Schwartz, R. S. (2007) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s021972000700259x · Cited by 36
The interaction of ENL with PAF1 mitigates polycomb silencing and facilitates murine leukemogenesis
Hetzner, K., García-Cuéllar, M.-P., Büttner, C., & Slany, R. K. (2017) · Blood · doi:10.1182/blood-2017-11-815035 · Cited by 36
lncRNA‑CCDC26, as a novel biomarker, predicts prognosis in acute myeloid leukemia
Chen, C., Wang, P., Mo, W., Zhang, Y., Zhou, W., Deng, T., Zhou, M., Chen, X., Wang, S., & Wang, C. (2019) · Oncology Letters · doi:10.3892/ol.2019.10591 · Cited by 41
“However, these molecular abnormalities are not yet comprehensively used as clinical prognostic molecular markers and therapeutic targets (22,23).”
BackgroundPathogenic and therapeutic roles of cytokines in acute myeloid leukemia
Sariani, O. K., Eghbalpour, S., Kazemi, E., Buzhani, K. R., & Zaker, F. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155508 · Cited by 39
Vergez, F., Largeaud, L., Bertoli, S., Nicolau-Travers, M.-L., Rieu, J., Vergnolle, I., Saland, E., Sarry, A., Tavitian, S., Huguet, F., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00712-7 · Cited by 40
“Interestingly, previous transcriptomic studies found at least 16 AML subgroups that were also associated with specific cytogenetic features and mutations [47].”
BackgroundEvi1 forms a bridge between the epigenetic machinery and signaling pathways
Yoshimi, A., & Kurokawa, M. (2011) · Oncotarget · doi:10.18632/oncotarget.304 · Cited by 39
Wouters, B. J., Sanders, M. A., Lugthart, S., Geertsma-Kleinekoort, W. M. C., van Drunen, E., Beverloo, H. B., Löwenberg, B., Valk, P. J. M., & Delwel, R. (2007) · Leukemia · doi:10.1038/sj.leu.2404795 · Cited by 36
Self-citationFu, L. N., Fu, H., Tian, L., Xu, K., Hu, K., Wang, J., Wang, J., Jing, H., Shi, J., & Ke, X. (2016) · Oncotarget · doi:10.18632/oncotarget.7489 · Cited by 41
“A microarray dataset that included 116 CN-AML samples and 5 NBM samples (GEO accession number GSE1159 ) was used for the expression analysis [27].”
Elevated TRIB 2 with NOTCH 1 activation in paediatric/adult T ‐ ALL
Hannon, M., Lohan, F., Erbilgin, Y., Sayitoğlu, M., O’Hagan, K., Mills, K., Özbek, U., & Keeshan, K. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09222.x · Cited by 39
“%) of all adult and childhood T-ALL patients and in rare AML cases (Weng et al, 2004; Breit et al, 2006; Wouters et al, 2007; Kraszewska et al, 2012).”
BackgroundGlüxam, T., Grandits, A. M., Schlerka, A., Nguyen, C. H., Etzler, J., Finkes, T., Fuchs, M., Scheid, C., Heller, G., Hackl, H., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235826 · Cited by 39
Fornerod, M. W. J., Ma, J., Noort, S., Liu, Y., Walsh, M. P., Shi, L., Nance, S., Liu, Y., Wang, Y., Song, G., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0049 · Cited by 35
“13 Gene expression, genomic classification, and leukemia stemness have all been shown to impact prognosis to varying extents in both adult and pediatric AML(5,18-23).”
Landrette, S. F., Madera, D., He, F., & Castilla, L. H. (2011) · Leukemia · doi:10.1038/leu.2010.301 · Cited by 37
“A fraction of inv16-AML samples also present activating mutations in genes encoding components of the receptor tyrosine kinase signaling pathways, including KIT and FLT3, and the their downstream GTPases NRAS and KRAS (4-7) (8).”
Xue, L., Pulikkan, J. A., Valk, P. J. M., & Castilla, L. H. (2014) · Blood · doi:10.1182/blood-2013-12-541730 · Cited by 36
“Furthermore, the expression profile of inv16 AML samples defines a unique signature, suggesting that CBFb-SMMHC redefines the molecular activity of targeted cells.(13) The inv(16) AML blasts have “secondary mutations” that cooperate with CBFb-SMMHC in leukemia.”
BackgroundSelf-citationGood cells gone bad: the cellular origins of cancer
Wang, J. C. Y. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.01.001 · Cited by 36
Gielen, S. C. J. P., Kühne, L. C., Ewing, P. C., Blok, L. J., & Burger, C. W. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01046 · Cited by 39
“Using this method only reliable results are generated for samples with an average intensity value of 30 or more, and therefore all values between 0 and 30 were set at 30 (Valk et al. 2004).”
MethodSeverens, J. F., Karakaslar, E. O., van der Reijden, B. A., Sánchez‐López, E., van den Berg, R. R., Halkes, C. J. M., van Balen, P., Veelken, H., Reinders, M. J. T., Griffioen, M., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02137-6 · Cited by 38
“AML subclassi fi cation is genetics-based, but transcriptomics holds immense potential to re fi ne AML classi fi cation further [1 – 3 , 10 – 12 ].”
A multigene array for measurable residual disease detection in AML patients undergoing SCT
Goswami, M., McGowan, K. S., Lu, K. Y., Jain, N. A., Candia, J., Hensel, N. F., Tang, J., Calvo, K. R., Battiwalla, M., Barrett, A. J., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.326 · Cited by 34
Jin, W., Wu, K., Yz, L., Yang, W.-T., Zou, B., Zhang, F., Zhang, J., & Wang, K.-K. (2012) · Oncogene · doi:10.1038/onc.2012.204 · Cited by 36
The future of high-grade glioma: Where we are and where are we going
Chamberlain, M. C., Rhun, É. L., & Taillibert, S. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.151331 · Cited by 39
“[148] Subgroups of AG can also be identified according to their molecular status using an unsupervised analysis of gene expression profiling.[97,274,293] Intrinsic glioma subtypes (IGS) have been reported to correlate better with outcome as compared with histology.”
ResultDissecting the Immune Landscape of Acute Myeloid Leukemia
Davidson-Moncada, J. K., Viboch, E., Church, S., Warren, S. E., & Rutella, S. (2018) · Biomedicines · doi:10.3390/biomedicines6040110 · Cited by 38
Byrne, A., Supple, M. A., Volden, R., Laidre, K. L., Shapiro, B., & Vollmers, C. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00643 · Cited by 43
Genua, C. D., Valletta, S., Buono, M., Stoilova, B., Sweeney, C., Rodríguez-Meira, A., Grover, A., Drissen, R., Meng, Y., Beveridge, R. D. D., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.022 · Cited by 37
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS
Huls, G. A., Chitu, D. A., Pabst, T., Klein, S. K., Stüssi, G., Griškevičius, L., Valk, P. J. M., Cloos, J. J., van de Loosdrecht, A. A., Breems, D. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002846 · Cited by 35
“CBFBMYH11, RUNX1-RUNX1T1, and FLT3 internal tandem duplication mutations were determined as previously described.(16,17) Mutations in 38 of 54 genes frequently mutated in hematologic malignancies were determined by targeted next-generation sequencing (NGS) with the TruSight Myeloid Sequencing panel, following the manu…”
MethodSelf-citationWalker, C. J., Mrózek, K., Özer, H. G., Nicolet, D., Kohlschmidt, J., Papaioannou, D., Genutis, L. K., Bill, M., Powell, B. L., Uy, G. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003727 · Cited by 40
“It was not surprising that, in our initial differential expression analysis comparing gene expressions between patients who relapsed and patients who maintained CR, clustering was driven by biallelic mutations in CEBPA and FLT3-ITDs, because these are known to be associated with outcome in CN-AML and have distinct exp…”
MethodResultBollaert, E., Claus, M., Vandewalle, V., Lenglez, S., Essaghir, A., Demoulin, J., & Havelange, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105153 · Cited by 34
Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?
Somervaille, T. C. P., & Cleary, M. L. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0579-8 · Cited by 40
Abbas, S., Sanders, M. A., Zeilemaker, A., Geertsma-Kleinekoort, W. M. C., Koenders, J. E., Kavelaars, F. G., Abbas, Z. G., Mahamoud, S., Chu, I. W. T., Hoogenboezem, R. M., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.095604 · Cited by 34
“, 21 AML cases from gene expression profiling clusters #4 and #15 (100% CEBPA mutant or CEBPA silenced(24)), 13 AML cases from cluster #9 [100% inv(16)] and 14 AML cases from cluster #10 (adverse prognosis).(20) In addition, DNA mapping array profiles, i.”
BackgroundMethodSelf-citationEndoplasmic Reticulum Stress-Related Factors Protect against Diabetic Retinopathy
Hu, W., Liu, R., Pei, H., & Li, B. (2011) · Experimental Diabetes Research · doi:10.1155/2012/507986 · Cited by 35
“It has been estimated that up to 20% of patients who have suffered from diabetes for 20 years remain free of the DR complication [35].”
BackgroundMicroarray analysis: basic strategies for successful experiments
Ness, S. A. (2007) · Molecular Biotechnology · doi:10.1007/s12033-007-0012-6 · Cited by 34
“Several laboratories have been successful at identifying patterns of gene expression that correlate with clinical outcome or define classes of tumors, similar to other cytogenetic markers [3, 17, 20 , 22].”
Reikvam, H., Fredly, H., Kittang, A. O., & Bruserud, Ø. (2013) · Toxins · doi:10.3390/toxins5020336 · Cited by 36
“The methodologies for clustering and other bioinformatical analyses of protein levels are in principal the same as for analysis of global gene expression analyses [74,76] that are used for subclassification of”
MethodKey roles of histone methyltransferase and demethylase in leukemogenesis
Yoshimi, A., & Kurokawa, M. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22972 · Cited by 35
“The ecotropic viral integration-site 1 (Evi1) is a unique gene in that it was the only gene whose overexpression was found to define a cluster in a large-scale gene expression profiling of AML, which accounts for approximately 10% of cases of AML [Valk et al., 2004].”
BackgroundInfluentialAndersson, A., Edén, P., Olofsson, T., & Fioretos, T. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-6 · Cited by 34
“Although global genomic studies have shown that various human leukemia subtypes display profoundly different gene expression profiles [2,4,5,10-12], we still lack important information about the biological and pathogenetic impact of these deregulated transcriptional programs.”
BackgroundGene expression profiles in acute myeloid leukemia with common translocations using SAGE
Lee, S., Chen, J., Zhou, G., Shi, R., Bouffard, G. G., Kocherginsky, M., Ge, X., Sun, M., Jayathilaka, N., Kim, Y. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509878103 · Cited by 38
Molecular pathogenesis of disease progression in MLL-rearranged AML
Kotani, S., Yoda, A., Kon, A., Kataoka, K., Ochi, Y., Shiozawa, Y., Hirsch, C. M., Takeda, J., Ueno, H., Yoshizato, T., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0253-3 · Cited by 34
Estrogen Receptors Alpha and Beta in Acute Myeloid Leukemia
Roma, A., & Spagnuolo, P. A. (2020) · Cancers · doi:10.3390/cancers12040907 · Cited by 38
“In AML, ERβ is more highly expressed than ERα in some AML patient gene sets [53,54].”
BackgroundTagliafico, E., Tenedini, E., Manfredini, R., Grande, A., Ferrari, F., Roncaglia, E., Bicciato, S., Zini, R., Salati, S., Bianchi, E., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404358 · Cited by 38
Oyan, A. M., Bø, T. H., Jonassen, I., Ulvestad, E., Gjertsen, B. T., Kalland, K., & Bruserud, Ø. (2005) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20044 · Cited by 34
Li, X., Xu, Y., Wang, Q., Lu, Y., Zheng, Y., Wang, Y., Lübbert, M., Zhao, K., & Chen, G. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20695 · Cited by 39
“…could be supported, at least partly, by two recent gene expression profiling analyses on BM or peripheral blood samples from AML patients (Ross et al., 2004; Valk et al., 2004), both of which did not list CX43 among the genes whose expression was significantly changed in AML1-ETO-positive leukemia.”
Proteomic analysis of childhood leukemia
Hegedus, C. M., Gunn, L., Skibola, C. F., Zhang, L., Shiao, R., Fu, S., Dalmasso, E. A., Metayer, C., Dahl, G. V. H., Buffler, P. A., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403897 · Cited by 38
Transcriptomics paving the way for improved diagnostics and precision medicine of acute leukemia
Lilljebjörn, H., Orsmark‐Pietras, C., Mitelman, F., Andersson, A., & Fioretos, T. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.013 · Cited by 48
Lazzarotto, D., & Candoni, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123306 · Cited by 33
“Furthermore, its effect seems to be dependent on multiple protein partners such as p53, altering the pro-apoptotic behavior of both proteins, or growth factor signaling proteins such as FLT3, as AML with the FLT3-ITD mutation has been shown to be associated with the highest levels of WT1 [5,25,26].”
BackgroundGrappling with the HOX network in hematopoiesis and leukemia
Glenda, J. M. (2008) · Frontiers in bioscience · doi:10.2741/3006 · Cited by 37
“Examination of gene expression levels in the leukemic state (primarily acute leukemia) shows global dysregulation of the HOX network in hematological malignancy (70-74).”
BackgroundSilkjær, T., Nørgaard, J. M., Aggerholm, A., Ebbesen, L. H., Kjeldsen, E., Hokland, P., & Nyvold, C. G. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12090 · Cited by 35
“The balanced translocations were identified by a multiplex RT-PCR using HemaVision-full kit (DNA Technology A/S, Risskov, Denmark) (33) or by realtime quantitative PCR (qPCR) identifying t(8, 21), inv(16), t(15,17), t(6,9), and dupMLL (34–36).”
BackgroundMethodThe role of Runx1/AML1 and Evi‐1 in the regulation of hematopoietic stem cells
Kumano, K., & Kurokawa, M. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21953 · Cited by 37
“5 with massive hemorrhage in the central nervous system and complete effacement of definitive hematopoiesis in the FL, though primitive erythropoiesis is preserved (Okuda et al., 1996; Wang et al., 1996).”
BackgroundClinical implications of molecular genetic aberrations in acute myeloid leukemia
Scholl, S., Fricke, H., Sayer, H. G., & Höffken, K. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0524-x · Cited by 35
“Based on known molecular markers, further GEP studies investigated whether signiWcant gene expression changes can be elucidated in AML with certain mutations (e.g., NPM1, FLT3-ITD) or in AML samples with high expression of prognostically relevant genes as BAALC or ERG.”
MethodInfluentialSox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia
Aue, G., Du, Y., Cleveland, S. M., Smith, S. B., Davé, U. P., Liu, D., Weniger, M. A., Metais, J. Y., Jenkins, N. A., Copeland, N. G., et al. (2011) · Blood · doi:10.1182/blood-2011-04-351528 · Cited by 36
“21,38 In addition, overexpression of DNAJC6, CCR1, and LCP1, also targeted by MSCV insertions in our study, have been shown to be associated with AMLs containing FLT3 internal tandem duplication, CEBPA, and t(8,21) mutations, respectively.”
BackgroundLo, M., Peterson, L. F., Yan, M., Cong, X., Jin, F., Shia, W.-J., Matsuura, S., Ahn, E.-Y. E., Komeno, Y., Ly, M., et al. (2012) · Blood · doi:10.1182/blood-2011-12-395335 · Cited by 39
Notch signaling in acute promyelocytic leukemia
Grieselhuber, N. R., Klco, J. M., Verdoni, A. M., Lamprecht, T. L., Sarkaria, S. M., Wartman, L. D., & Ley, T. J. (2013) · Leukemia · doi:10.1038/leu.2013.68 · Cited by 33
“In this report we extended the observation that the Notch ligand JAG1 is overexpressed in APL cells 16,18,19,29-31 by performing a functional study of the role of Notch signaling in both human and murine APL samples.”
Dombret, H., Preudhomme, C., & Boissel, N. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283257b18 · Cited by 34
Roos, J., Grösch, S., Werz, O., Schröder, P., Ziegler, S., Fulda, S., Paulus, P., Urbschat, A., Kuhn, B. R., Maucher, I. V., et al. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.001 · Cited by 36
ccSVM: correcting Support Vector Machines for confounding factors in biological data classification
Li, L., Rakitsch, B., & Borgwardt, K. M. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr204 · Cited by 33
“A synthetic dataset was also generated to Data : P.Warnat et al. (2005) myeloid leukemia (AML): Bullinger et al. (2004) and Valk et al. (2004).”
Gene Expression With Prognostic Implications in Cytogenetically Normal Acute Myeloid Leukemia
Baldus, C. D., & Bullinger, L. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.006 · Cited by 33
Albanesi, J., Noguera, N. I., Banella, C., Colangelo, T., Marinis, E. D., Leone, S., Palumbo, O., Voso, M. T., Ascenzi, P., Nervi, C., et al. (2020) · Cells · doi:10.3390/cells9112423 · Cited by 35
Strassberger, V., Gutbrodt, K. L., Krall, N., Roesli, C., Takizawa, H., Manz, M. G., Fugmann, T., & Neri, D. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.01.022 · Cited by 35
“[37] Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, et al.”
BackgroundNoordermeer, S. M., Sanders, M. A., Gilissen, C., Tönnissen, E., van der Heijden, A., Döhner, K., Bullinger, L., Jansen, J. H., Valk, P. J. M., & van der Reijden, B. A. (2011) · Blood · doi:10.1182/blood-2011-06-359182 · Cited by 32
“*Favorable karyotype: t(8;21), t(15;17), and inv(16).”
BackgroundMethodSelf-citationGenomic Characterization of Acute Leukemias
Chiaretti, S., Gianfelici, V., Ceglie, G., & Foà, R. (2014) · Medical Principles and Practice · doi:10.1159/000362793 · Cited by 35
Casorelli, I., Tenedini, E., Tagliafico, E., Blasi, M. F., Giuliani, A., Crescenzi, M., Pelosi, E., Testa, U., Peschle, C., Mele, L., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404376 · Cited by 32
Boller, D., Doepfner, K. T., Laurentiis, A. D., Stücklin, A. G., Marinov, M., Shalaby, T., Depledge, P., Robson, A. G., Saghir, N., Hayakawa, M., et al. (2012) · PubMed · Cited by 34
RetractedIntegrative Meta-Analysis of Differential Gene Expression in Acute Myeloid Leukemia
Miller, B., & Stamatoyannopoulos, J. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009466 · Cited by 35
“[4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25, 26,27,28,29,30,31,32,33] However, these studies have not been systematically compared.”
BackgroundCharacterization of upregulated adhesion GPCRs in acute myeloid leukemia
Yang, J., Wu, S. K., & Alachkar, H. (2019) · Translational research · doi:10.1016/j.trsl.2019.05.004 · Cited by 36
IL2RA Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia
Nguyen, C. H., Schlerka, A., Grandits, A. M., Koller, E., van der Kouwe, E., Vassiliou, G. S., Staber, P. B., Heller, G., & Wieser, R. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0531 · Cited by 32
Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal
Zhao, X., Chen, A., Yan, X., Zhang, Y., He, F., Hayashi, Y., Dong, Y., Rao, Y., Li, B., Conway, R. M., et al. (2014) · Blood · doi:10.1182/blood-2013-03-489575 · Cited by 35
“We also analyzed RUNX1, CBFb, and MEN1 (Menin) mRNA levels in published AML patient samples.(35) Metaanalysis showed that RUNX1, CBFb, and MEN1 mRNA levels are not decreased inM4/M5 subtypes with MLL translocations compared with the same subtype without MLL translocations, consistent with our AML cell line data (suppl…”
ResultGilby, D. C., Goodeve, A. C., Winship, P. R., Valk, P. J. M., Delwel, R., & Reilly, J. T. (2007) · Leukemia · doi:10.1038/sj.leu.2404864 · Cited by 31
Self-citationMahadevan, D., DiMento, J., Croce, K. D., Riley, C., George, B. L., Fuchs, D. A., Mathews, T., Wilson, C., & Lobell, M. (2006) · American Journal of Hematology · doi:10.1002/ajh.20690 · Cited by 31
BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis
Eid, M., Attia, M. A., Abdou, S., El-Shazly, S., ELAHWAL, L., Farrag, W. F., & MAHMOUD, L. (2009) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2009.01168.x · Cited by 31
“Recently, various molecular markers and global gene expression profiling have been investigated to improve risk profile characterization of AML with norml cytogenetics (Bullinger et al., 2004; Valk et al., 2004).”
BackgroundClinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia
Vaikari, V. P., Du, Y., Wu, S. K., Zhang, T., Metzeler, K. H., Batcha, A. M. N., Herold, T., Hiddemann, W., Akhtari, M., & Alachkar, H. (2019) · Haematologica · doi:10.3324/haematol.2018.207001 · Cited by 31
Meester‐Smoor, M. A., Janssen, M. J. F. W., Grosveld, G. C., de Klein, A., van IJcken, W. F. J., Douben, H., & Zwarthoff, E. C. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn168 · Cited by 31
“Overexpression of MN1 is observed in acute myeloid leukemia (AML) specified by the chromosomal aberration inv(16) (1,2), in some AMLs overexpressing the transcription factor ecotropic viral integration (EVI1) ( 2 ) and in some adult AMLs with normal karyotype (3).”
BackgroundInfluentialTaskesen, E., Babaei, S., Reinders, M. M., & de Ridder, J. (2015) · BMC Bioinformatics · doi:10.1186/1471-2105-16-s4-s5 · Cited by 30
“AML is a heterogeneous disease for which groups of patients can be identified with common cytogenetic or molecular abnormality (denoted as subtypes) [3].”
BackgroundMethodApplication of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
Zhang, Z., Huang, J., Zhang, Z., Shen, H., Tang, X., Wu, D., Bao, X., Xu, G., & Chen, S. (2024) · Biomarker Research · doi:10.1186/s40364-024-00600-1 · Cited by 32
“Several other studies [47, 59–62] based on GEP also identified molecular subgroups with or without correlation to mutations and karyotypes, which may guide better therapeutic selections.”
ResultSorror, M. L., & Appelbaum, F. R. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2013.827418 · Cited by 31
LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia
Tatsumi, G., Kawahara, M., Yamamoto, R., Hishizawa, M., Kito, K., Suzuki, T., Takaori‐Kondo, A., & Andoh, A. (2019) · Leukemia · doi:10.1038/s41375-019-0614-6 · Cited by 30
Decroocq, J., Birsen, R., Montersino, C., Chaskar, P., Mano, J., Poulain, L., Friedrich, C., Alary, A., Guermouche, H., Sahal, A., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01541-0 · Cited by 30
“From RNAseq in 52 samples from the cohort, we did not detect a clear clustering of RAS+ samples, as reported [20], suggesting that the impact of RAS activation on gene expression was low with respect to other molecular drivers in AML.”
ResultKMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis Inhibition
Xu, J., Zhong, A., Zhang, S., Chen, M., Zhang, L., Hang, X., Zheng, J., Wu, B., Deng, X., Pan, X., et al. (2023) · Advanced Science · doi:10.1002/advs.202206098 · Cited by 37
Genome-Wide Analysis of Transcriptional Reprogramming in Mouse Models of Acute Myeloid Leukaemia
Bonadies, N., Foster, S. D., Chan, W.-I., Kvinlaug, B. T., Spensberger, D., Dawson, M. A., Spooncer, E., Whetton, A. D., Bannister, A. J., Huntly, B. J. P., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016330 · Cited by 33
“G) Oncomine analysis of three independent gene expression datasets (GEO accession numbers: GSE1729, GSE425, GSE1159) [31,33,34] demonstrates that GATA2 expression levels are not higher in AML subtypes characterised by minimal differentiation (FAB AML-M0). doi:10.1371/journal.pone.0016330.g004 PLoS ONE | www.plosone.or…”
Influentialter Elst, A., Ma, B., Scherpen, F. J. G., de Jonge, H. J. M., Douwes, J., Wierenga, A. T. J., Schuringa, J. J., Kamps, W. A., & de Bont, E. S. J. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0402 · Cited by 30
Wiesner, S. M., Freese, A. B., & Ohlfest, J. R. (2005) · Neurosurgical FOCUS · doi:10.3171/foc.2005.19.4.4 · Cited by 30
Belle, W. V., Ånensen, N., Haaland, I., Bruserud, Ø., Høgda, K., & Gjertsen, B. T. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-198 · Cited by 30
“The FAB classification is recently shown to be reflected in the gene expression of the AML cells [38,39].”
BackgroundNext-Generation Sequencing of Cancer Genomes: Back to the Future
Walter, M. J., Graubert, T. A., DiPersio, J. F., Mardis, E. R., Wilson, R. K., & Ley, T. J. (2009) · Personalized Medicine · doi:10.2217/pme.09.52 · Cited by 31
Wang, M., Lindberg, J., Klevebring, D., Nilsson, C. C., Lehmann, S., Grönberg, H., & Rantalainen, M. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy021 · Cited by 29
Integrative Model-based clustering of microarray methylation and expression data
Kormáksson, M., Booth, J. G., Figueroa, M. E., & Melnick, A. M. (2012) · The Annals of Applied Statistics · doi:10.1214/11-aoas533 · Cited by 29
DeKelver, R. C., Lewin, B., Lam, K., Komeno, Y., Yan, M., Rundle, C. W., Lo, M., & Zhang, D. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003765 · Cited by 32
“regulation in human AML, we again examined available patient data and find that KLF6 expression is specifically higher in t(8;21)+ leukemia samples (Figure S1B and [34]).”
InfluentialJuopperi, T. A., Bienzle, D., Bernreuter, D. C., Vernau, W., Thrall, M. A., & McManus, P. M. (2010) · Veterinary Pathology · doi:10.1177/0300985810389317 · Cited by 29
Metadata
- Authors
- Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., & Delwel, R.
- Affiliations
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-15
- Volume
- 350
- Issue
- 16
- Pages
- 1617-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110502951
- Cited by
- 1,370
- References
- 30
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 27 · 2023: 40 · 2022: 30 · 2021: 59 · 2020: 49 · 2019: 50 · 2018: 40 · 2017: 39 · 2016: 66 · 2015: 53 · 2014: 64 · 2013: 72 · 2012: 86
- FWCI
- 63.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Erasmus Medisch Centrum
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, gene expression profiling, prognostic stratification, molecular signatures, patient clustering, inv(16), CEBPA mutation, chromosomal abnormalities, normal karyotype, treatment outcomes
- MeSH terms
- Acute Disease, Adult, Algorithms, Chromosome Aberrations, Female, Humans, Karyotyping, Leukemia, Myeloid, Male, Middle Aged, Mutation, Prognosis, Software, Gene Expression, Multivariate Analysis, Cluster Analysis, Survival Analysis, Oligonucleotide Array Sequence Analysis, Cytogenetic Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.